BlossomHill Therapeutics (BLSM) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Sagimet Biosciences Series A is the larger company by market cap ($633.2 million vs $555.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | SGMT |
|---|---|---|
| Share price | $17.48 | $8.93 |
| Market cap | $555.60M | $633.21M |
| 1-day change | +3.55% | +0.11% |
| YTD return | — | +50.84% |
| 1-year return | — | +3.60% |
| EPS (TTM) | $-4.83 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $11.45 |
| 52-week low | $15.25 | $4.50 |
| Distance from 52-week high | -37.55% | -22.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +102.52% | +212.54% |
| Average volume | 258.35K | 1.24M |
| Shares outstanding | 31.78M | 70.34M |
| Employees | 69 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
BLSM vs SGMT FAQ
Which is bigger, BlossomHill Therapeutics or Sagimet Biosciences Series A?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $633.21M compared with $555.60M for BlossomHill Therapeutics (BLSM).
Are BlossomHill Therapeutics and Sagimet Biosciences Series A in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.